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A series of 110 cases of oral squamous cell carcinoma (SCC) together with six lymph node and one distant metastatic lesions was
analysed for expression of survivin, a recent apoptosis inhibitor, by immunohistochemistry and Western blotting. In total, 91 cases
(82.7%) of carcinoma and all metastasis (seven cases, 100%) were positive for survivin expression, with weighted survivin scores
ranging from 1 to 4. In contrast, normal oral epithelium did not express survivin. There was no significant correlation between survivin
expression and age, sex, tumour size, the presence of lymph node and distant metastases. Survivin expression was increased in poorly
differentiated tumours, even if differences were not statistically significant. In contrast, when analysed for prognostic significance,
patients with low survivin expression had statistically significant better survival rates than the group with high survivin expression
(Po0.05). These data suggest that survivin expression may identify cases of oral SCC with more aggressive and invasive phenotype.
British Journal of Cancer (2003) 89, 2244–2248. doi:10.1038/sj.bjc.6601402 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: survivin; squamous cell carcinoma; oral mucosa; mouth; apoptosis
                                            
The frequency of squamous cell carcinoma (SCC) of the oral
mucosa (OSCC) is rapidly increasing. In particular, OSCC
constitutes the most frequent malignant tumour of the oral cavity.
The incidence of metastasis depends on the degree of cellular
differentiation, deep invasion, and site of the primary tumour.
However, the clinical behaviour of the single cases of tumours is
difficult to predict basing on classical histopathological parameters
alone. Biological markers that can identify the lesions with more
aggressive phenotype and worse prognosis still need to be
identified.
Carcinogenesis is a multistage process involving the activation
of oncogenes and the inactivation of tumour suppressor genes. In
this context, most human tumours are characterised by an
imbalance of regulatory mechanisms controlling cell cycle
progression, cell death/viability balance, and apoptosis.
Apoptosis has become a basic tool in developing cancer research
and establishing new cancer strategies. Apoptosis, or programmed
cell death, is a genetically controlled process, which maintains
developmental morphogenesis (Vaux et al, 1994), and homeostasis
of differentiated organisms by removing senescent, unneeded, or
dangerous cells (Sternberg, 1997). Aberrations of this process
leading to aberrantly reduced cell death are thought to participate
in cancer by promoting increased resistance to therapy and
favouring the insurgence of transforming mutations (Jameson,
1998).
Considerable interest has recently focused on the identification
of regulators of apoptosis, which may potentially influence the cell
death/cell viability balance in cancer. In addition to pro- and
antiapoptotic bcl-2 molecules (Reed, 1998), a second gene family of
inhibitor of apoptosis (IAP) has been recently identified (Crook
et al, 1993). Highly evolutionarily conserved from viruses to
mammalian cells (Crook et al, 1993; Ambrosini et al, 1997), IAP
proteins target a downstream step in apoptosis by inhibiting the
terminal effector caspase-3 and -7 (Deveraux et al, 1997; Tamm
et al, 1998), and by interfering with processing/activation of the
pinnacle caspase, caspase-9.
Previous studies demonstrated that expression of antiapoptotic
bcl-2 in oral SCC could potentially contribute to tumour
progression. This was suggested by the increased expression of
bcl-2 protein and mRNA in poorly differentiated oral SCCs as
compared with histological normal oral epithelium (Chen et al,
2000).
Survivin is a recently characterised IAP protein, which is
abundantly expressed in most solid and haematological malig-
nancies, but undetectable in normal adult tissues (Ambrosini et al,
1997). Interference with survivin function induces pleiotropic cell-
division defects and apoptosis (Li et al, 1999), suggesting a
potential role at the interface between cell division and apoptosis
control. In retrospective trials, survivin expression correlated with
unfavourable neuroblastoma (Adida et al, 1998a), reduced overall
survival in primitive colorectal (Kawasaki et al, 1998) and
recurrent colorectal cancer (Sarela et al, 2000), non-small-cell
lung cancer (Monzo et al, 1999), breast cancer (Tanaka et al, 2000),
and increased rates of recurrences in bladder cancer (Swana et al,
1999). Consistent with a critical role of apoptosis inhibition in
tumour progression, overexpression of survivin in model cancer Revised 5 September 2003; accepted 16 September 2003
*Correspondence: Prof L Lo Muzio, Institute of Dental Sciences, Faculty
of Medicine, University of Ancona, Via Carelli 28, 71100 Foggia, Italy;
E-mail: llomuzio@tin.it
British Journal of Cancer (2003) 89, 2244–2248






























ycell types provided a broad cytoprotective mechanism, counter-
acting apoptosis induced by FAS/TNF legation, proapoptotic Bax,
effector caspases, and various chemotherapeutic drugs (Tamm
et al, 1998).
In this study, we sought to investigate the potential expression
and impact of survivin protein in oral SCC. We found that survivin
is expressed in about 80% of oral SCC, and that its degree of
expression correlates with a more aggressive phenotype.
MATERIALS AND METHODS
Selection of cases
A total of 110 samples from paraffined and 10 from frozen
specimens of primary oral SCC, seven from paraffined specimens
of lymph node (six cases) and tissue metastases (one case) of
OSCCs included in this study were used. Specimens were fixed in
10% neutral-buffered formalin.
None of the patients had been treated previously. They received
surgical treatment with curative intention. No case in this study
concerned patients with contemporaneous multicentric lesions.
Clinical data was reviewed to record sex and age of the patient, and
site and size of the lesion. The group consisted of 80 men and 30
women with a mean age of 59.6 years (range 39–78). There were 38
stage I, 29 stage II, 14 stage III, and 29 stage IV. Only 76 patients
were analysed for survival rates (the follow-up time was sufficient
for statistical analysis, 43 years). Survival was calculated from the
date of operation to the date of the latest follow-up visit or
death due to cancer. Patients who died of postoperative complica-
tions within 30 days were excluded. The histopathological grading
was assessed on paraffin haematoxylin–eosin (H&E)-stained
sections. Tumour extent was classified according to the TNM
system by UICC (UICC, 1987), and tumours were divided into
grades 1, 2, and 3 using the WHO classification of histological
differentiation.
In all, 10 paraffined and five frozen specimens of healthy oral
mucosa were obtained from patients who had undergone routine
oral surgical procedures (such as impacted third molars,
metaprotesic reactive epithelial hyperplasia, etc.) with the in-
formed consent of the donors. The use of archived human tissues
conformed to an informed consent protocol that had been
reviewed and approved by the institutional review board of the
University of Naples Federico II, Italy.
Immunohistochemistry
Serial sections (4mm) from formalin-fixed, paraffin-embedded
blocks were cut for each case, and one section stained with H&E
was used to confirm the histopathological diagnosis. Only sections
containing sufficient epithelium to assess the antibody reactivity
with 1000 cells were considered for this study.
Immunohystochemistry was then performed on the remaining
sections mounted on poly-L-lysine-coated glass slides. Immuno-
histochemical staining was carried out with a rabbit polyclonal
antibody supplied by NOVUS (NOVUS Biologicals, Littleton, CO,
USA) raised against full-length recombinant survivin characterised
in previous studies (Grossman et al, 1999a; Grossman et al, 2001),
using the standard streptavidin–biotin–peroxidase complex
technique using the Dako LSAB kit (DAKO A/S, Carpinteria, CA,
USA) after antigen retrieval by pressure cooking. Briefly,
deparaffined sections were immersed in a 10
 3 M sodium citrate
buffer (pH 6.0) after bringing the solution to a boil in a pressure
cooker, and then heated two times for 3min each at a 10-min
interval while keeping the pressure indicator valve rising. After
quenching in 3% hydrogen peroxide and blocking, the sections
were incubated with primary antibody diluted 1:50 overnight at
41C. Biotinylated anti-rabbit immunoglobulin and streptavidin
conjugated to horseradish peroxidase were subsequently applied.
Finally, 3,30-diaminobenzidine was used for colour development,
and haematoxylin was used for counterstaining. Negative control
slides in the absence of primary antibody were included for each
staining.
The results of the immunohistochemical staining were evaluated
separately by two observers, blind to the histologic diagnosis of the
single cases and especially to the follow-up data for the respective
patients.
To quantitate the survivin expression, 300 cells were examined
in at least five areas at  400 magnification and a mean percentage
of positive tumour cells was determined assigning cases to one of
the five following categories: (a) 0, o5%; (b) 1, 5–25%; (c) 2, 26–
50%; (d) 3, 51–75%; and (e) 4, 475%. Cases with score of 0 were
considered as negative, cases with scores of 1–4 as positive.
Statistical analysis
Data were analysed using Prism (ver 3.0 for windows) and Stanton
A. Glantz (ver 3.0 for dos) softwares. Significant differences
(Po0.05) between groups were determined using nonparametric
Comparisons Test (Kruskall–Wallis test) and Mann–Whitney test
and also w
2 test. Survival analysis was computed comparing
negative (score 0) and low expressing (score 1) with medium
(score 2–3) and high (score 4) expressing survivin. Survival curves
were analysed according to the method of Kaplan–Meier, and for
differences between curves the P-value was calculated by the log-
rank test. A P-value of less than 0.05 was accepted as statistically
significant.
Western blot analysis
Frozen tissues from five samples of oral mucosa and 10 from oral
SCCs were homogenised directly into lysis buffer containing 50mM
HEPES, 150mM NaCl, 1mM EDTA, 1mM EGTA, 10% glycerol, 1%
Triton-X-100 (1:2 weight/volume), 1mM phenylmethylsulphonyl
fluoride (PMSF), 1mg aprotinin, 0.5mM sodium orthovanadate,
20mM sodium pyrophosphate (Sigma Chemical Co, St Louis, MO,
USA), and clarified by centrifugation at 14000  10min. Protein
concentrations were estimated using a modified Bradford assay
(Bio-Rad, Melville, NY, USA).
In all, 50mg of total protein extracts was boiled in Laemmli
buffer for 5min before electrophoresis. The samples were
subjected to SDS–PAGE (14% polyacrylamide) under reducing
conditions. After electrophoresis, proteins were transferred to
nitrocellulose membrane (Immobilon Millipore Corporation, Bed-
ford, MA, USA); complete transfer was assessed using prestained
protein standards (Bio-Rad, Melville, NY, USA). The membranes
were treated for 2h with blocking solution (5% no fat powdered
milk in 25mM Tris, pH 7.4; 200mM NaCl; 0.5% Triton X-100, TBS/
T), and then the membranes were incubated for 12h at 41C with
the primary antibody against survivin. After washing with TBS/T
and TBS, membranes were incubated with the horseradish
peroxidase-conjugated secondary antibody (1:5000) for 1h (at
room temperature) and the reaction was detected with enhanced
chemiluminescence (ECL) system (Amersham Life Science, UK).
After stripping, membranes were incubated with a monoclonal
antibody against beta-actin 1:5000 for 1h at room temperature
(Sigma-Aldrich, St. Louis, MO, USA) to ensure an equivalent
protein loading in each lane.
RESULTS
Survivin expression in normal oral mucosa
Normal oral mucosa specimens showed positivity only in sporadic
cells of basal and parabasal layers and were considered negative for
Survivin and oral SCC
L Lo Muzio et al
2245





























ysurvivin expression by immunohistochemistry (score¼0), in
agreement with previous observations (Lo Muzio et al, 2001)
Survivin expression in oral SCC
Immunohistochemical staining for survivin was observed in 20–
100% of cancer cells. The immunostaining was prevalently
cytoplasmic in poorly differentiated cases with sporadic prominent
nuclear staining in well-differentiated areas, as already reported in
cervical mucosa (Frost et al, 2002). However, in this study,
differences in the intracellular pattern of staining that resulted
were not statistically significant; for this reason, we recorded the
specimens as positive without considering the intracellular
localisation of the signal (cytoplasmic or nuclear). In contrast,
neighbouring normal tissues did not express survivin. After
survivin score, 91 cases (82.7%) of oral mucosa cancers were
defined as positive, with weighted survivin scores ranging from 1
to 4 (Figures 1A–D). Expression of B16.5 kDa survivin in tissue
extracts of oral SCC was also demonstrated by Western blotting
(Figure 2). All the cases of metastasis enclosed in this study
showed survivin positivity.
There was no significant correlation between survivin expres-
sion and age, sex, tumour size, or the presence of lymph node and
distant metastases (Table 1). Survivin expression was often
Figure 1 (A) A case of moderate-differentiated oral SCC showing no staining for survivin, score 0 (ABC, 150 )( B) A case of moderate/low-
differentiated oral SCC showing staining for survivin, score 1 (ABC, 106 )( C) A case of moderate differentiated oral SCC showing prevalent cytoplasmatic
staining for survivin, score 2 (ABC, 150 )( D) A case of oral SCC with low grade of differentiation showing cytoplasmatic positivity for survivin, score 4
(ABC, 106 )( E) A case of oral SCC with low grade of differentiation showing cytoplasmatic positivity for survivin at high power, score 4 (ABC, 250 )( F)
A case of oral SCC with low grade of differentiation showing cytoplasmatic positivity for survivin at high power, score 4 (ABC, 400 )( G) A case of oral
SCC with low grade of differentiation showing cytoplasmatic positivity for survivin at high power, score 4 (ABC, 400 )( H) A case of lymph node
metastasis from oral SCC with definite immunostaining for survivin in tumor cells (ABC, 106 ).
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yincreased in poor differentiated tumours, but differences that
resulted were not statistically significant. In contrast, when
analysed for prognostic significance, patients with low survivin
expression had better survival rates than the group with medium
and high survivin expression (Figure 3). This difference of survival
rates was statistically significant (Po0.05) and the Hazard was
0.2696 with 95% confidence interval ranging from 0.02666 to
0.85475.
DISCUSSION
In this study, we have shown that a novel antiapoptosis gene,
survivin, is prominently expressed in more than 80% of oral SCC.
In particular, survivin expression often increased in poorly
differentiated tumours, even if differences were not statistically
significant. Of more interest, the high survivin expression that
resulted correlated with poor survival rates.
Compelling experimental evidence recently suggested that
deregulation of apoptosis plays a critical role in the onset and
progression of cancer (Thompson, 1995). This conclusion
stemmed primarily from the effects of deregulated bcl-2 expression
in follicular lymphoma, which resulted in aberrantly prolonged B-
cell survival, increased accumulation of transforming mutations,
and accelerated transition to more aggressive and therapy-resistant
disease (Hua et al, 1988). A similar paradigm has also been
suggested for other solid malignancies, thus prompting the search
for additional molecular markers potentially influencing the cell
death/cell viability balance in cancer. In this context, recent studies
identified the IAP family protein, survivin, as a novel apoptosis
inhibitor selectively overexpressed in most human cancers, but not
in normal tissues (Ambrosini et al, 1997; Adida et al, 1998b).
Differently from bcl-2 family molecules, IAP proteins are thought
to block a highly evolutionarily conserved step in cell death by
binding and inhibiting terminal effector caspases-3 and –7
(Deveraux et al, 1998), thus providing a separate and nonredun-
dant pathway of cell viability in cancer.
Figure 2 (A) Western blot detection of survivin protein in the tissue
extracts of normal mucosa (lane 1), well-differentiated SCC (lanes 2), and
poorly differentiated SCC (lanes 3 and 4). Proteins (50mg/lane) was
resolved by SDS–PAGE, transferred to nitrocellulose membrane and then
incubated with antibody raised against survivin. A specific band was
observed sizing about 16.5kDa by comparison with comigrating size
markers (Bio-Rad, Melville, NY, USA). (B)The same membrane was
stripped and incubated with antibody raised against beta-actin, sizing about
42kDa (Sigma-Aldrich). The blots are representative of three separate
assays.
Table 1 Statistical analysis of survivin score expression and associated clinicopathological findings in oral SCCs
Survivin expression Score 0 Score 1 Score 2 Score 3 Score 4
Variables No. n. (%) no. (%) no. (%) no. (%) no. (%) no. (%) Mean S.d. S.e. P
Cases 110 91 (82.7) 19 (17.2) 16 (14.5) 27 (24.5) 24 (21.8) 24 (21.8)
Age
o60 years 36 30 (83) 6 (5.4) 5 (4.5) 11 (10) 9 (8.1) 5 (4.5) 2.056 1.286 0.214
460 years 74 61 (82) 13 (11.8) 11 (10) 16 (14.5) 15 (13.6) 19 (17.2) 2.216 1.436 0.166 0.5310
a
Sex
Male 80 66 (82) 14 (12.7) 11 (10) 19 (17.2) 18 (16.3) 18 (16.3) 2.188 1.397 0.1562 0.7521
a
Female 30 25 (83) 5 (4.5) 5 (4.5) 8 (7.2) 6 (5.4) 6 (5.4) 2.100 1.373 0.2507
Grading
G1 23 18 (78) 5 (5) 2 (1.8) 4 (3.6) 5 (4.5) 7 (6.3) 2.304 1.550 0.3232
G2 62 51 (82) 11 (10) 12 (10.9) 18 (16.3) 10 (9) 11 (10) 1.968 1.342 0.1705 0.1787
b
G3 25 22 (88) 3 (2.7) 2 (1.8) 5 (4.5) 9 (8.1) 6 (5.4) 2.520 1.295 0.2590
Size (cm)
o1.5 36 30 (83) 6 (5.4) 3 (2.7) 11 (10) 8 (7.2) 8 (7.2) 2.250 1.360 0.226 0.6684
a
41.5 74 61 (82) 13 (11.8) 13 (11.8) 16 (14.5) 16 (14.5) 16 (14.5) 2.122 1.404 0.163
Lymph node metastasis
Negative
Positive (N+) 68 57 (83) 11 (10) 10 (9) 18 (16.3) 14 (12.7) 15 (13.6) 2.176 1.371 0.1662 0.9361
a
Lymph node metastasis 42 34 (80) 8 (7.2) 6 (5.4) 9 (8.1) 10 (9) 9 (8.1) 2.143 1.424 0.2197
Staging
I 38 30 (78) 8 (7.2) 4 (3.6) 10 (9) 4 (3.6) 12 (10.9) 2.211 1.527 0.2478 0.2436
b
II 29 23 (79) 6 (5.4) 4 (3.6) 8 (7.2) 8 (7.2) 3 (2.7) 1.931 1.307 0.2428
III 14 13 (92) 1 (0.9) 1 (0.9) 2 (1.8) 6 (5.4) 4 (3.6) 2.786 1.188 0.3176
IV 29 25 (86) 4 (3.6) 7 (6.3) 7 (6.3) 6 (5.4) 5 (4.5) 2.034 1.322 0.2456
aMann–Whitney test.
bNonparametric comparisons test (Kruskall–Wallis test).
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Figure 3 Survival analysis was computed comparing low expressing
(score 0–1) with medium/high (score 2–4) expressing survivin. Patients
with negative or low score had better survival rates than patients with
medium and high score for survivin expression. This difference of survival
rates was statistically significant (Po0.05).
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yHere, the presence of survivin in more aggressive and poorly
differentiated variants of oral SCC confirms and extends earlier
reports of survivin expression in skin cancers (Chiodino et al,
1999; Grossman et al, 1999b), and suggests its potential predictive/
prognostic impact for disease progression. In model cancer cells,
expression of the survivin gene was shown to occur exclusively in
the G2/M phase in a strict cell cycle-regulated manner (Li et al,
1998), thus potentially explaining a preferential expression of
survivin in poorly differentiated and metastatic SCC, likely to
exhibit high proliferative potential. At a molecular level, survivin
localised to mitotic spindle microtubules of dividing cells (Li et al,
1998), in a reaction required to preserve apoptosis inhibition.
Moreover, in vitro targeting experiments using survivin antisense
or a dominant negative survivin mutant demonstrated that this
unique topography was also required for proper cell division
timing and cell progression through mitosis. Consistent with this
view, RNA interference of a survivin-homologous BIR1 protein in
model organisms also resulted in embryonic lethality due to a
profound defect of cytokinesis (Fraser et al, 1999). Altogether,
these data suggest that survivin expression in aggressive SCC may
provide a strong growth advantage factor for tumour progression,
affording both protection from broad apoptosis-inducing stimuli/
drugs and maintaining proper mitotic progression of the
proliferating population. Consistent with this view, recent studies
(Glinsky et al, 1997) demonstrated that highly metastatic cancers
exhibit a higher resistance to apoptotic cell death as compared to
low-metastatic counterparts (Glinsky et al, 1997).
In summary, these data suggest that survivin expression in oral
SCC may identify patients at risk of more aggressive and
disseminated disease. This may be relevant for the institution of
closer follow-up protocols and/or alternative combined therapeu-
tic regimens. These findings reiterate the importance of deregula-
tion of apoptosis as a critical pathogenetic component of tumour
progression, and identify survivin as a potential novel molecular
marker of aggressive neoplasia.
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